These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 37186489)

  • 1. Species distribution and antifungal susceptibility of clinical Aspergillus isolates: A multicentre study in Taiwan, 2016-2020.
    Wang HC; Hsieh MI; Choi PC; Wu WL; Wu CJ;
    Mycoses; 2023 Aug; 66(8):711-722. PubMed ID: 37186489
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular identification and antifungal susceptibility of clinically relevant and cryptic species of
    Nargesi S; Jafarzadeh J; Najafzadeh MJ; Nouripour-Sisakht S; Haghani I; Abastabar M; Ilkit M; Hedayati MT
    J Med Microbiol; 2022 Apr; 71(4):. PubMed ID: 35451946
    [No Abstract]   [Full Text] [Related]  

  • 3. Aspergillus fumigatus Clinical Isolates Carrying CYP51A with TR34/L98H/S297T/F495I Substitutions Detected after Four-Year Retrospective Azole Resistance Screening in Brazil.
    Pontes L; Beraquet CAG; Arai T; Pigolli GL; Lyra L; Watanabe A; Moretti ML; Schreiber AZ
    Antimicrob Agents Chemother; 2020 Feb; 64(3):. PubMed ID: 31871090
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug Sensitivity and Resistance Mechanism in Aspergillus Section
    Hashimoto A; Hagiwara D; Watanabe A; Yahiro M; Yikelamu A; Yaguchi T; Kamei K
    Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28607016
    [No Abstract]   [Full Text] [Related]  

  • 5. High Prevalence of Azole-Resistant Aspergillus fumigatus Among Iranian Cystic Fibrosis Patients: Should We Be Concerned?
    Bandegani A; Abastabar M; Sharifisooraki J; Abtahian Z; Vaseghi N; Khodavaisy S; Fakharian A; Khalilzadeh S; Modaresi MR; Haghani I; Ahmadi A; Ghazanfari M; Valadan R; Badali H
    Mycoses; 2024 Sep; 67(9):e13791. PubMed ID: 39239666
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Azole resistance in Aspergillus species in Southern Taiwan: An epidemiological surveillance study.
    Chen YC; Kuo SF; Wang HC; Wu CJ; Lin YS; Li WS; Lee CH
    Mycoses; 2019 Dec; 62(12):1174-1181. PubMed ID: 31549427
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro antifungal susceptibility profile and genotypic characterization of clinical Aspergillus isolates in Eastern China on behalf of Eastern China Invasive Fungi Infection Group.
    Lin H; Guo J; Li Y; Xiao C; Hu L; Chen H; Lu X; Wu W
    Med Mycol; 2023 Sep; 61(9):. PubMed ID: 37580143
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the Sensititre YeastOne and CLSI M38-A2 Microdilution Methods in Determining the Activity of Amphotericin B, Itraconazole, Voriconazole, and Posaconazole against Aspergillus Species.
    Wang HC; Hsieh MI; Choi PC; Wu CJ
    J Clin Microbiol; 2018 Oct; 56(10):. PubMed ID: 30093391
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multicenter Study of Susceptibility of Aspergillus Species Isolated from Iranian University Hospitals to Seven Antifungal Agents.
    Badiee P; Boekhout T; Zarei Mahmoudabadi A; Mohammadi R; Ayatollahi Mousavi SA; Najafzadeh MJ; Soltani J; Hashemi J; Diba K; Ghadimi-Moghadam A; Salimi-Khorashad AR; Shokohi T; Amin Shahidi M; Ghasemi F; Jafarian H
    Microbiol Spectr; 2022 Jun; 10(3):e0253921. PubMed ID: 35579442
    [TBL] [Abstract][Full Text] [Related]  

  • 10. First determination of azole resistance in Aspergillus fumigatus strains carrying the TR34/L98H mutations in Turkey.
    Özmerdiven GE; Ak S; Ener B; Ağca H; Cilo BD; Tunca B; Akalın H
    J Infect Chemother; 2015 Aug; 21(8):581-6. PubMed ID: 26048062
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro activity of a novel broad-spectrum antifungal, E1210, tested against Aspergillus spp. determined by CLSI and EUCAST broth microdilution methods.
    Pfaller MA; Duncanson F; Messer SA; Moet GJ; Jones RN; Castanheira M
    Antimicrob Agents Chemother; 2011 Nov; 55(11):5155-8. PubMed ID: 21844312
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Determination of Azole Resistance and TR
    Güngör Ö; Sampaio-Maia B; Amorim A; Araujo R; Erturan Z
    Mycopathologia; 2018 Dec; 183(6):913-920. PubMed ID: 30187246
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Species identification and antifungal susceptibility testing of Aspergillus strains isolated from patients with otomycosis in northern China.
    Jing R; Yang WH; Xiao M; Li Y; Zou GL; Wang CY; Li XW; Xu YC; Hsueh PR
    J Microbiol Immunol Infect; 2022 Apr; 55(2):282-290. PubMed ID: 33839057
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Species Distribution and Antifungal Susceptibilities of
    Badali H; Cañete-Gibas C; McCarthy D; Patterson H; Sanders C; David MP; Mele J; Fan H; Wiederhold NP
    J Clin Microbiol; 2022 May; 60(5):e0028022. PubMed ID: 35400175
    [No Abstract]   [Full Text] [Related]  

  • 15. Species Identification and
    Imbert S; Normand AC; Ranque S; Costa JM; Guitard J; Accoceberry I; Bonnal C; Fekkar A; Bourgeois N; Houzé S; Hennequin C; Piarroux R; Dannaoui E; Botterel F
    Antimicrob Agents Chemother; 2018 May; 62(5):. PubMed ID: 29439956
    [No Abstract]   [Full Text] [Related]  

  • 16. In vitro activity of the novel antifungal compound F901318 against difficult-to-treat Aspergillus isolates.
    Buil JB; Rijs AJMM; Meis JF; Birch M; Law D; Melchers WJG; Verweij PE
    J Antimicrob Chemother; 2017 Sep; 72(9):2548-2552. PubMed ID: 28605488
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multicenter Study of Azole-Resistant Aspergillus fumigatus Clinical Isolates, Taiwan
    Wu CJ; Liu WL; Lai CC; Chao CM; Ko WC; Wang HC; Dai CT; Hsieh MI; Choi PC; Yang JL; Chen YC
    Emerg Infect Dis; 2020 Apr; 26(4):804-806. PubMed ID: 32186508
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prospective survey of Aspergillus species isolated from clinical specimens and their antifungal susceptibility: A five-year single-center study in Japan.
    Toyotome T; Saito S; Koshizaki Y; Komatsu R; Matsuzawa T; Yaguchi T
    J Infect Chemother; 2020 Feb; 26(2):321-323. PubMed ID: 31564504
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aspergillus welwitschiae; an otomycosis predominant agent, new epidemiological and antifungal susceptibility data from Iran.
    Halvaeezadeh M; Jalaee GA; Fatahinia M; Mahmoudabadi AZ
    Microb Pathog; 2023 Aug; 181():106180. PubMed ID: 37257666
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular Identification and In Vitro Antifungal Susceptibility of Aspergillus Isolates Recovered from Otomycosis Patients in Western China.
    Zhang L; Wang X; Houbraken J; Mei H; Liao W; Hasimu H; Liu W; Deng S
    Mycopathologia; 2020 Jun; 185(3):527-535. PubMed ID: 32346838
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.